Background Chronic Myeloid Leukemia (CML) progresses through chronic, accelerated, and blast crisis phases, making disease stratification and therapeutic response prediction challenging. IGF2BP3 (Insulin-like Growth Factor 2 mRNA Binding Protein 3) has emerged as a potential prognostic biomarker due to its involvement in RNA stability and oncogenic pathways. Methods This study employed a multi-platform approach, including immunohistochemistry (IHC), ELISA, qRT-PCR, and Western blotting, to evaluate IGF2BP3 expression in 121 CML patient samples across disease stages. Advanced artificial intelligence (ChatGPT 4.0) and statistical tools (R-Studio) were utilized to analyze correlations between IGF2BP3 levels, clinical parameters, and treatment responses. Results IGF2BP3 expression progressively increased from the chronic to the blast crisis phase, correlating with disease severity and resistance to therapy. IHC staining intensity and serum levels of IGF2BP3 were highest in the blast crisis phase, confirmed by qRT-PCR and Western blotting. AI-powered regression analysis revealed a strong correlation between IGF2BP3 levels, P210 translocation percentages, and blast counts. Non-responders to therapy exhibited significantly elevated IGF2BP3 levels, underscoring its potential as a marker for treatment resistance. Conclusions IGF2BP3 is a reliable biomarker for CML disease progression, therapeutic resistance, and patient stratification. Targeting IGF2BP3 may offer novel therapeutic opportunities, particularly in advanced disease stages. This study demonstrates the utility of integrating AI in biomarker research to enhance precision and actionable insights.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The research proposal entitled "To Decipher the Molecular Role of Insulin-like Growth Factor in Chronic Myeloid Leukemia" has undergone a thorough ethical review by the Institutional Ethics Committee (IEC) at King George's Medical University, U.P., Lucknow (Registration No.: ECR/262/Inst/UP/2013/RR-19). The clarification provided for the comments raised during the initial review was evaluated, and the proposal has been approved for execution as per ethical guidelines. The decision reflects the compliance of the research objectives and methodology with established ethical standards for biomedical research. Researchers are requested to cite the assigned reference code: XVI-PGTSC-IIA/P34 in all future correspondence related to this study. For further queries or communication, the ethics committee can be contacted at King George's Medical University, U.P., Lucknow.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript